If you or someone you know takes Elmiron and has noticed changes in vision, you may be concerned about possible eye-related side effects. Adverse event reports have documented cases of pigmentary maculopathy in long-term users, prompting clinical guidelines for monitoring. This page provides a checklist of reported symptoms and follow-up tests to discuss with your healthcare provider.
Pigmentary maculopathy associated with Elmiron is characterized by pigmentary changes in the retina, specifically in the macula, the central region responsible for sharp, detailed vision. The FDA-approved labeling for Elmiron states that these changes have been identified with long-term use, with most cases occurring after three years or more of treatment, though shorter durations have also been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Visual symptoms reported in these cases include difficulty reading, slow adjustment to low or reduced light environments, and blurred vision (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The full visual consequences of these pigmentary changes are not yet fully characterized, but the labeling notes that they may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Diagnosis relies on comprehensive ophthalmologic evaluation. The labeling recommends obtaining a detailed ophthalmologic history in all patients before starting Elmiron. For those with a family history of hereditary pattern dystrophy, genetic testing should be considered. For patients with pre-existing ophthalmologic conditions, a comprehensive baseline retinal examination—including color fundoscopic photography, ocular coherence tomography (OCT), and auto-fluorescence imaging—is recommended prior to therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). For all patients, a baseline retinal examination (including OCT and auto-fluorescence imaging) is suggested within six months of initiating treatment and periodically thereafter (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). If pigmentary changes develop, the risks and benefits of continuing treatment should be re-evaluated.
Elmiron is a semi-synthetic polysaccharide with anticoagulant and anti-inflammatory properties, though its exact mechanism in interstitial cystitis is not fully understood. In clinical trials, Elmiron was evaluated in 2,627 patients (2,343 women, 262 men, 22 unknown) with a mean age of 47 years (range 18 to 88), of whom 581 (22%) were over 60 years of age (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Serious adverse events occurred in 33 patients (1.3%), and deaths in 6 (0.2%), though these were generally attributed to other illnesses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Post-marketing adverse event reports from the FDA Adverse Event Reporting System (FAERS) provide a broader picture. The most frequently reported adverse events associated with Elmiron include maculopathy (1,382 reports), off-label use (1,361 reports), retinal pigmentation (607 reports), dry age-related macular degeneration (560 reports), pigmentary maculopathy (442 reports), and drug ineffective (327 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). Other common reports include pain, nausea, headache, alopecia, diarrhea, fatigue, depression, anxiety, and visual impairment (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). Notably, the FAERS data also list retinal dystrophy (141 reports) and neovascular age-related macular degeneration (141 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON).
The exact mechanism by which Elmiron causes pigmentary maculopathy remains unclear. The FDA labeling states that "the etiology is unclear," though cumulative dose appears to be a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). A 21-year real-world analysis of FAERS data, published in a peer-reviewed journal, provides additional insights. This study found that the reporting frequency and strongest signals for Elmiron were overwhelmingly concentrated in the 'Eye Disorders' system organ class, with pigmentary maculopathy demonstrating an exceptionally high reporting odds ratio (ROR) (https://pubmed.ncbi.nlm.nih.gov/41657558/). The analysis also identified significant non-ocular signals, including depression and anxiety (https://pubmed.ncbi.nlm.nih.gov/41657558/). A gender-specific analysis revealed that maculopathy signals were prominently observed among females, while males exhibited distinct associations with gastrointestinal and urinary adverse events (https://pubmed.ncbi.nlm.nih.gov/41657558/). The time-to-onset analysis (n=297) revealed a median onset time of 1,715 days (approximately 4.7 years), with a Weibull model (β=0.62) indicating a decreasing hazard rate over time, meaning the risk of developing maculopathy does not increase proportionally with continued exposure but rather appears to be highest in the early years of long-term use (https://pubmed.ncbi.nlm.nih.gov/41657558/). The majority of reported cases (68.1%) were classified as serious adverse events (https://pubmed.ncbi.nlm.nih.gov/41657558/).
The FDA labeling for Elmiron includes a Warnings section that specifically addresses retinal pigmentary changes, noting the association with long-term use and cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). It advises caution in patients with pre-existing retinal pigment changes, as examination findings may confound diagnosis and follow-up (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The labeling also recommends baseline and periodic ophthalmologic monitoring, as well as re-evaluation of risks and benefits if pigmentary changes develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). However, the warning does not specify a precise threshold for cumulative dose or duration that triggers risk, leaving clinicians to rely on clinical judgment. For affected patients, causation considerations are complex. The FAERS data show a strong signal for pigmentary maculopathy, but these reports do not establish causation in individual cases. The time-to-onset analysis indicates a median latency of nearly five years, with a decreasing hazard over time, suggesting that the risk is not simply a function of cumulative dose but may involve individual susceptibility factors (https://pubmed.ncbi.nlm.nih.gov/41657558/). The labeling notes that pigmentary changes may be irreversible, underscoring the importance of early detection and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The timeline between exposure and documented harm is characterized by a long latency. The median onset of 1,715 days (approximately 4.7 years) from the time-to-onset analysis aligns with the labeling's observation that most cases occur after three years or more of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593; https://pubmed.ncbi.nlm.nih.gov/41657558/). Cases with shorter durations have also been reported, indicating that some patients may be more vulnerable (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The decreasing hazard rate over time (β=0.62) suggests that the risk of developing maculopathy is not constant but is highest in the early years of long-term therapy, after which it may decline (https://pubmed.ncbi.nlm.nih.gov/41657558/). This pattern is consistent with a drug-induced toxicity that affects a subset of susceptible individuals. In summary, the evidence supports a causal association between long-term Elmiron use and pigmentary maculopathy, with a distinct long-latency risk profile. The FDA labeling provides warnings and monitoring recommendations, but the irreversible nature of the retinal changes and the high proportion of serious adverse events (68.1%) highlight the need for vigilance in patients on chronic therapy. Clinicians should weigh the benefits of Elmiron for interstitial cystitis against the risk of vision-threatening maculopathy, particularly in patients with pre-existing retinal conditions or those on long-term treatment.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Elmiron pigmentary maculopathy is a retinal condition associated with long-term use of Elmiron (pentosan polysulfate sodium), characterized by pigmentary changes in the macula that can lead to vision impairment. The FDA has issued a warning about this risk, noting that most cases occur after three years or more of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
Symptoms include difficulty reading, slow adjustment to low or reduced light environments, and blurred vision. The visual changes may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
Diagnosis involves a comprehensive ophthalmologic evaluation, including color fundoscopic photography, ocular coherence tomography (OCT), and auto-fluorescence imaging. Baseline and periodic monitoring are recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.